Skip to main content
Premium Trial:

Request an Annual Quote

AITBiotech Licenses Multiple Assays

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Singapore genomics service firm AITBiotech announced it has licensed molecular assays developed by research institutes under Singapore's Agency for Science Technology and Research (A*STAR).

The assays were licensed from Exploit Technologies, the marketing and commercialization arm of A*STAR.
The agreement covers dengue/chikungunya multiplex detection kits and a Mycobacterium tuberculosis detection kit. The kits are used with PCR systems.

The assays were developed by Masafumi Inoue and his colleagues at A*STAR's Experimental Therapeutics Centre, AITBiotech said in a statement.

The company also has acquired the license to an H1NI whole-genome mutation detection system, developed by Christopher Wong and his team at the Genome Institute of Sinagpore. The test had a call rate of 99 percent and accuracy of 99.99 percent in testing of samples from Singapore and Mexico, according to AITBiotech.

The acquired assays are being used by hospitals in Thailand, it said, and are being evaluated by other hospitals in Singapore, Hong Kong, Malaysia, and Indonesia.

Terms of the agreements were not disclosed.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.